ASLAN Pharmaceuticals’ (ASLN) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reiterated their buy rating on shares of ASLAN Pharmaceuticals (NASDAQ:ASLN) in a report released on Monday morning, Benzinga reports. They currently have a $9.00 target price on the stock.

Separately, Piper Sandler reissued an overweight rating and issued a $10.00 target price (down from $15.00) on shares of ASLAN Pharmaceuticals in a research note on Wednesday, March 13th.

ASLAN Pharmaceuticals Stock Performance

Shares of ASLN opened at $0.51 on Monday. The stock has a fifty day moving average price of $0.61 and a two-hundred day moving average price of $0.77. ASLAN Pharmaceuticals has a 52-week low of $0.39 and a 52-week high of $4.69. The company has a market cap of $8.26 million, a price-to-earnings ratio of -0.18 and a beta of 1.45.

Institutional Investors Weigh In On ASLAN Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in ASLN. UBS Group AG acquired a new stake in shares of ASLAN Pharmaceuticals in the 4th quarter valued at $326,000. Renaissance Technologies LLC boosted its position in shares of ASLAN Pharmaceuticals by 574.1% in the 2nd quarter. Renaissance Technologies LLC now owns 475,896 shares of the company’s stock worth $236,000 after purchasing an additional 405,296 shares during the last quarter. Citigroup Inc. bought a new position in shares of ASLAN Pharmaceuticals in the 4th quarter worth $104,000. Virtu Financial LLC boosted its position in shares of ASLAN Pharmaceuticals by 389.6% in the 4th quarter. Virtu Financial LLC now owns 88,106 shares of the company’s stock worth $32,000 after purchasing an additional 70,109 shares during the last quarter. Finally, Bank of America Corp DE boosted its position in shares of ASLAN Pharmaceuticals by 34.4% in the 1st quarter. Bank of America Corp DE now owns 259,722 shares of the company’s stock worth $233,000 after purchasing an additional 66,544 shares during the last quarter. 58.82% of the stock is owned by institutional investors and hedge funds.

ASLAN Pharmaceuticals Company Profile

ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal antibody that targets the IL-13 receptor a1 subunit which is being developed for the treatment of atopic dermatitis and other immunology indications; and ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune diseases.